An arcane regulatory term known as skinny labeling may have a funny ring to it, but to generic drug makers, it is no laughing matter.
What has the generic industry upset is a recent court ruling that, legal experts say, could effectively negate a key aspect of a decades-old law which makes it possible to supply Americans with many of cheaper generic alternatives to pricey brand-name medicines.
With the flood, over the last few decades, of judges appointed based on ideological conformity rather than intellectual capacity, I fear it may become increasingly difficult for the federal bench to make sound decisions in complex cases such as this. O tempora, o mores.
Comments are closed.